All In Biotech

Drug Trial Radar · NCT06502743

First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

Phase 2 Study of First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Sep 12, 2024

Primary completion

Dec 27, 2027

Study completion Dec 27, 2027

Sponsor

Lead sponsor
Yonsei UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Onconic Therapeutics Inc.; Merck Sharp & Dohme LLC
First posted
Jul 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is listed below. Part A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial cancer. Feasibility is defined as a dose-limiting toxicity (DLT) rate less than or equal to 33%. Part B (Randomization Phase) : To evaluate the efficacy of pembrolizumab and nesuparib combination/ pembrolizumab monotherapy as maintenance therapy in patients with MMR-proficient advanced stage and recurrent endometrial cancer. Efficacy will be assessed by investigator assessed progression free survival (PFS) as assessed by RECIST 1.1.

Conditions

  • Endometrial Cancer
  • Recurrent Endometrial Carcinoma
  • Endometrial Carcinoma
  • Gynecologycal Cancer
  • Endometrial Neoplasms

Interventions

  • NesuparibDrug

    Nesuparib 150mg or 100mg, QD, PO

  • PembrolizumabDrug

    Pembrolizumab 400mg, IV, Q6W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicitiesTime frame: Assessed during 21days from day 1 of first combination maintenance treatment cycle (i.e., 21 days of Cycle 8 from day 1)
  2. Overall distribution of progression-free survivalTime frame: Approximately 11.01 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Severance hospital

    Seoul, South Korea · Recruiting

  • Korea University Guro Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul Asan Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • National Cancer Center

    Goyang-si, Kyeonggi-do, South Korea · Recruiting

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.